Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Western New England University","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Western New England University and Quercis Pharma Sign Exclusive Worldwide License Agreements","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals for Zafirlukast

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Western New England University

            Contact Supplier
            • Deals
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            Details:

            Zafirlukast (Accolate®) is in a class of medications known as leukotriene receptor antagonists (LTRAs) that work by blocking the action of certain natural substances that cause swelling and tightening of the airways.

            Lead Product(s): Zafirlukast

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Quercis Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY